Cassava Sciences, Inc. SAVA · Stock Open Cassava Sciences, Inc. in new tab
Cassava Sciences, Inc. Analysis (SAVA)
Is Cassava Sciences, Inc. a good investment? Cassava Sciences, Inc. (SAVA) is currently trading at 1.32 USD.
Earnings Schedule: Cassava Sciences, Inc. is expected to release its next earnings report on May 7, 2026. The market consensus estimate for Forward EPS is -1.77.
Investor FAQ
Does Cassava Sciences, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Cassava Sciences, Inc.?
Cassava Sciences, Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be May 7, 2026. The company currently has a trailing EPS of -2.22.
Company Profile
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
| Year | Total Dividends |
|---|---|
| ▸2012 |
0.75 USD
|
| Dec. 24, 2012 | 0.7500 |
| ▸2010 |
2.00 USD
|
| Dec. 13, 2010 | 2.0000 |
| Split Date | Split Ratio to 1 |
|---|---|
| May 10, 2017 | 0.14 |
Community Discussion